Skip to main content
. 2018 Jan 22;103(4):1302–1309. doi: 10.1210/jc.2017-00283

Figure 3.

Figure 3.

Changes in serum circulating levels of (left) sclerostin and (right) DKK-1 over a 104-week treatment period with teriparatide. Data presented as mean percentage of change and 95% CI from baseline (0) (n = 20) at several time points. *P < 0.05 compared with baseline.